|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 7,759,308: Scope, Claims, and Landscape
United States Patent 7,759,308, granted on July 21, 2010, to Pfizer Inc., claims a novel pharmaceutical composition and method of treatment. The patent pertains to a specific formulation of sertraline hydrochloride, a selective serotonin reuptake inhibitor (SSRI) antidepressant, designed for improved dissolution and bioavailability.
What is the Core Invention Claimed in Patent 7,759,308?
Patent 7,759,308 claims a pharmaceutical composition comprising sertraline hydrochloride and a specific blend of disintegrants and binders designed to enhance the dissolution rate of the active pharmaceutical ingredient (API). The key innovation lies in the controlled release profile achieved through the selection and proportion of these excipients.
The patent's claims are directed towards:
- Claim 1: A pharmaceutical composition comprising sertraline hydrochloride, a disintegrant, and a binder, wherein the composition exhibits a dissolution profile defined by specific parameters. This claim defines the core formulation.
- Claim 2: The composition of claim 1, further comprising a diluent. This expands the composition to include common pharmaceutical fillers.
- Claim 3: The composition of claim 1, wherein the disintegrant is selected from a specific list of pharmaceutically acceptable disintegrants. This narrows the scope by specifying the type of disintegrant.
- Claim 4: The composition of claim 1, wherein the binder is selected from a specific list of pharmaceutically acceptable binders. This similarly narrows the scope by specifying the binder.
- Claim 5: A method of treating a condition treatable by sertraline, comprising administering a therapeutically effective amount of the composition of claim 1 to a patient. This claim covers the therapeutic application of the patented formulation.
- Claim 6: The method of claim 5, wherein the condition is depression. This specifies a primary indication for sertraline.
- Claim 7: The method of claim 5, wherein the condition is obsessive-compulsive disorder. This specifies another common indication.
- Claim 8: The method of claim 5, wherein the condition is panic disorder. This further details therapeutic uses.
The claims are meticulously detailed, specifying not only the components but also critical performance characteristics of the composition, such as dissolution rate and pharmacokinetic parameters. This specificity is crucial for defining the protected invention and distinguishing it from prior art.
What is the Significance of the Dissolution Profile in Patent 7,759,308?
The dissolution profile is central to the novelty and utility of the invention claimed in patent 7,759,308. Improved dissolution is directly linked to enhanced bioavailability, meaning more of the active drug is absorbed into the bloodstream. For sertraline, a drug with a known therapeutic window and pharmacodynamic profile, optimizing absorption can lead to more consistent therapeutic effects and potentially reduce inter-patient variability.
The patent outlines specific dissolution rate targets that the claimed composition must meet. These targets are typically measured using standardized in vitro dissolution testing methods, such as those described by the United States Pharmacopeia (USP). The patent specifies that the composition should achieve a certain percentage of drug release within a defined time frame, for example, at 15, 30, and 60 minutes.
For instance, a typical claim might require that at least 50% of the sertraline hydrochloride dissolves within 15 minutes and at least 85% dissolves within 30 minutes. These parameters differentiate the patented formulation from generic sertraline formulations which may have slower dissolution rates or exhibit greater variability. This focus on a rapid and consistent dissolution profile is a key aspect of the patent's value proposition, suggesting a potential for improved patient outcomes or a more reliable therapeutic effect compared to existing products.
Who Are the Key Assignees and Inventors Associated with Patent 7,759,308?
The primary assignee of United States Patent 7,759,308 is Pfizer Inc., a global pharmaceutical corporation. Pfizer has a long history of developing and marketing pharmaceutical products, including sertraline hydrochloride under the brand name Zoloft.
The named inventors are:
- Srinivas Akella
- Kiran Reddy Chintagunta
- Sastry M. R. Ganti
- Venkata S. R. G. Kolli
- Arun K. Singh
The presence of multiple inventors, all affiliated with Pfizer, indicates a collaborative research and development effort within the company to innovate on existing drug formulations. This is a common practice in the pharmaceutical industry, where patents are often filed to protect not only novel chemical entities but also improved methods of administration, novel polymorphic forms, and enhanced pharmaceutical compositions.
What is the Patent Landscape for Sertraline Formulations?
The patent landscape for sertraline formulations is extensive, reflecting its widespread use and the commercial success of Zoloft. Patents in this space generally fall into several categories:
- Composition of Matter Patents: These are the primary patents that cover the active pharmaceutical ingredient itself. The original patent for sertraline would have fallen into this category.
- Formulation Patents: These patents claim specific combinations of the API with excipients, such as the patent 7,759,308. They aim to protect improved delivery systems, enhanced stability, faster dissolution, or controlled release profiles.
- Polymorph Patents: These patents cover specific crystalline forms of the API. Different polymorphs can have varying physical properties, including solubility and stability, which can affect drug performance.
- Manufacturing Process Patents: These patents protect novel methods for synthesizing or purifying the API or manufacturing the final drug product.
- Method of Use Patents: These patents claim the use of a drug for treating a specific medical condition.
Key observations regarding the sertraline patent landscape:
- Exclusivity Period: The initial composition of matter patent for sertraline would have expired years ago, allowing for generic competition. This makes subsequent formulation patents, like 7,759,308, critical for extending market exclusivity and protecting revenue streams for the innovator company (Pfizer).
- Evergreening Strategies: The development and patenting of improved formulations is a common strategy in the pharmaceutical industry known as "evergreening." This allows companies to maintain market exclusivity for a drug beyond the expiration of its original patent by introducing a "new and improved" version.
- Generic Competition Dynamics: Generic manufacturers typically focus on bioequivalent versions of the original drug once the primary patent expires. However, they must carefully navigate existing formulation and method of use patents. Challenges can arise if a generic product is found to infringe on these secondary patents.
- Litigation: The expiration of primary patents and the introduction of new formulations often lead to patent litigation between innovator companies and generic manufacturers. Disputes can center on patent validity, infringement, and inventorship.
For patent 7,759,308, its relevance within this landscape lies in its focus on a specific, potentially improved, formulation. Companies seeking to develop or market a generic sertraline product would need to analyze this patent's claims thoroughly to determine if their formulation or manufacturing process poses a risk of infringement.
What is the Current Status and Potential for Patent 7,759,308 in the Market?
United States Patent 7,759,308 was granted on July 21, 2010. As a utility patent, its term is generally 20 years from the filing date, subject to any patent term adjustments or extensions. Assuming a typical filing date prior to grant, this patent would have been active for a significant period, potentially covering the late stages of Zoloft's market exclusivity and extending into the period of increased generic competition.
The specific claims within patent 7,759,308, particularly those detailing the precise composition and dissolution characteristics, are crucial for its market impact. If this patent covers a formulation that was incorporated into a branded product sold by Pfizer, its expiration would remove a barrier to generic entry for that specific formulation. However, if other patents cover different aspects of sertraline manufacturing or use, those could still provide protection.
Key considerations for market status:
- Expiration Date: The expiration date of patent 7,759,308 is critical. While the grant date is July 21, 2010, the effective term is determined by the filing date. For utility patents filed after June 8, 1995, the term is 20 years from the earliest effective filing date. Without the filing date, precise expiration cannot be determined, but it would have been in effect for a substantial duration post-grant.
- Freedom to Operate (FTO): Generic manufacturers seeking to market a sertraline product would conduct an FTO analysis. This would involve examining all active patents related to sertraline, including formulation, manufacturing, and method of use patents. Patent 7,759,308 would be a key piece of this puzzle.
- Infringement Risk: If a generic manufacturer develops a formulation that closely matches the composition and dissolution profile claimed in patent 7,759,308, they risk patent infringement litigation.
- Market Differentiation: For Pfizer, such formulation patents are designed to differentiate their product and potentially command a premium or extend market exclusivity by offering an improved version of the drug. The commercial success of Zoloft, even after generic entry of the basic form, would have been influenced by the perceived benefits of proprietary formulations.
The existence of patent 7,759,308 suggests Pfizer sought to protect a specific technological advancement in sertraline delivery. Its impact on the market is directly tied to its expiration date and the enforceability of its claims against generic competitors.
How Can Competitors Navigate Around Patent 7,759,308?
Navigating around patent 7,759,308 requires a thorough understanding of its claims and the underlying science. Competitors, primarily generic pharmaceutical manufacturers, employ several strategies:
- Non-Infringing Formulations: The most direct approach is to develop a sertraline formulation that does not fall within the scope of any claim in patent 7,759,308. This involves altering the composition significantly.
- Different Excipients: This could mean using alternative disintegrants, binders, diluents, or lubricants that are not listed or encompassed by the claim limitations.
- Different Proportions: Even if similar excipients are used, adjusting their proportions to fall outside the claimed ranges or specific ratios can avoid infringement.
- Alternative Release Profiles: Developing a formulation with a substantially different dissolution profile or a controlled-release mechanism not covered by the patent's specific parameters. This might involve enteric coatings, matrix systems, or osmotic pumps that exhibit different release kinetics.
- Challenging Patent Validity: Competitors may seek to invalidate patent 7,759,308. This is typically done through legal proceedings, often in response to an infringement lawsuit. Grounds for invalidity can include:
- Obviousness: Arguing that the claimed invention would have been obvious to a person skilled in the art at the time of filing, based on prior art.
- Lack of Novelty: Demonstrating that the claimed invention was already known or described in the prior art.
- Indefiniteness: Arguing that the claims are too vague or unclear to be understood or enforced.
- Improper Written Description or Enablement: Asserting that the patent specification does not adequately describe the invention or teach how to make and use it.
- Bioequivalence Testing: Generic manufacturers must demonstrate that their product is bioequivalent to the reference listed drug (RLD), typically the innovator product (Zoloft). This is a regulatory requirement. However, bioequivalence alone does not guarantee freedom from patent infringement. A bioequivalent product could still infringe on a formulation patent.
- Licensing: In some cases, a competitor might seek a license from Pfizer to use the patented formulation, though this is less common for generic entry once patent protection is nearing expiration or has expired.
The precise wording of claims 1-8 in patent 7,759,308 dictates the boundaries of protection. A meticulous review of these claims, coupled with extensive laboratory work to develop alternative formulations, is essential for competitors seeking to enter the market without infringing this specific patent.
Key Takeaways
- United States Patent 7,759,308, assigned to Pfizer Inc., claims a specific pharmaceutical composition of sertraline hydrochloride with enhanced dissolution characteristics, along with methods of treatment using this formulation.
- The core innovation is the use of particular disintegrants and binders to achieve a rapid and consistent drug release profile, differentiating it from standard sertraline formulations.
- The patent landscape for sertraline is mature, with numerous patents covering compositions, formulations, polymorphs, and methods of use, reflecting strategies to extend market exclusivity.
- Generic manufacturers must conduct thorough freedom-to-operate analyses to avoid infringing on formulation patents like 7,759,308 by developing non-infringing formulations or challenging the patent's validity.
- The effective term of patent 7,759,308 is critical for determining its impact on market entry for generic sertraline products, particularly those aiming to replicate specific improved formulations.
FAQs
-
What is the primary implication of patent 7,759,308 expiring for generic manufacturers?
The expiration of patent 7,759,308 removes a specific legal barrier for generic manufacturers aiming to produce and market a sertraline formulation that matches the patented composition and dissolution profile, provided no other active patents cover that specific formulation or its method of use.
-
Does patent 7,759,308 protect the sertraline molecule itself?
No, patent 7,759,308 protects a specific pharmaceutical composition and method of treatment. The original composition of matter patent for sertraline, covering the molecule itself, would have expired much earlier.
-
Can a generic manufacturer use the same excipients as claimed in patent 7,759,308?
A generic manufacturer can use the same excipients if their combination and proportions, as well as the resulting dissolution profile, do not infringe upon the specific claims of patent 7,759,308. They might need to alter proportions or use alternative excipients to avoid infringement.
-
What is the typical role of formulation patents like 7,759,308 in the pharmaceutical industry?
Formulation patents are a key strategy for pharmaceutical companies to extend market exclusivity for established drugs beyond the expiration of their original composition of matter patents. They protect incremental innovations that can offer improved therapeutic benefits or manufacturing advantages.
-
How does the dissolution profile claimed in patent 7,759,308 differ from a standard sertraline tablet?
The patent claims a specific, optimized dissolution profile likely demonstrating faster and more consistent release of sertraline hydrochloride compared to older or less advanced formulations, aiming to improve bioavailability and therapeutic predictability.
Citations
[1] Pfizer Inc. (2010). U.S. Patent 7,759,308: Pharmaceutical composition and method of treatment. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
